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Phospholipases A2 (PLA2s) represent one of the largest groups of lipid-modifying enzymes. Over the years, signiﬁcant advances
have been made in understanding their potential physiological and pathological functions. Depending on their calcium
requirement for activation, PLA2s are classiﬁed into calcium dependent and independent. This paper mainly focuses on brain
calcium-independent PLA2 (iPLA2) and on the mechanisms by which they inﬂuence neuronal function and regulate synaptic
plasticity. Particular attention will be given to the iPLA2γ isoform and its role in the regulation of synaptic glutamate receptors. In
particular, the paper discusses the possibility that brain iPLA2γ deﬁciencies could destabilise normal synaptic operation and might
contribute to the aetiology of some brain disorders. In this line, the paper presents new data indicating that iPLA2γ deﬁciencies
accentuate AMPA receptor destabilization and tau phosphorylation, which suggests that this iPLA2 isoform should be considered
as a potential target for the treatment of Tau-related disorders.
1.Introduction
The nervous system is formed by integrated neuronal
circuits which all require constant adaptation for stabilizing
their activities in the face of perturbations that alter, for
instance, neuronal excitability. Phenomena that conform
to this deﬁnition include the activity-dependent regulation
of intrinsic neuronal ﬁring properties [1, 2], pre- and
postsynaptic forms of excitatory synaptic plasticity, such
as synaptic scaling, that adjust all of a neuron’s excitatory
synapses up or down in the right direction to stabilize
ﬁring [3, 4]; the balancing of excitation and inhibition
within neuronal networks [5, 6]; compensatory changes
in synapse number [7]; apposition of presynaptic and
postsynaptic elements [4] and metaplastic mechanisms that
adjust long-term changes in synaptic operation [8, 9]. In
general, it is believed that the ﬁnal reﬁnements of neuronal
circuits rely on the stabilization of functionally appro-
priate connections and the elimination of inappropriate
ones.
While the molecular mechanisms of synapse formation
have been extensively studied, very little is known about the
molecular mechanisms that are responsible for stabilization
of synaptic connections. Over the recent years, however,
it has been proposed that the level of AMPA subtype of
glutamate receptors found at neuronal connections might
be a crucial component controlling both stabilization of
presynaptic inputs and postsynaptic spine morphogenesis
(see [10]). In the present paper, we will focus on the
possibility that a speciﬁc PLA2 isoform can interact with
AMPA receptor properties to contribute to synaptic stabi-
lization. We will, in this line, present some new information
indicating that iPLA2γ deﬁciency might undermine the nor-
mal stabilizing mechanisms underlying memory formation
in the hippocampus and contribute to Alzheimer’s disease
pathology.
2.iPLA2 Isoforms, Long-Term Potentiation,
and Memory Stabilization
Phospholipases A2 (PLA2s) constitute a large and diverse
group of enzymes with broad biological functions, ranging
from membrane synthesis and turnover to the generation of2 Neural Plasticity
Table 1: Calcium-independent group VI phospholipase A2 (iPLA2).
Group Source Molecular mass (kDa) Feature Alternate names
VIA-1 Human/Murine 84-85 8 ankyrin repeats iPLA2
VIA-2 Human/Murine 88–90 7 ankyrin repeats iPLA2β
VIB Human/Murine 88–91 Membrane-bound iPLA2γ
VIC Human/Murine 146 Integral membrane protein iPLA2δ
VID Human 53 Acylglycerol transacylase, triglycerol lipase iPLA2ε
VIE Human 57 Acylglycerol transacylase, triglycerol lipase iPLA2ξ
VIF Human 28 Acylglycerol transacylase, triglycerol lipase PLA2η
signaling molecules. So far, more than 20 isoforms of PLA2
with diverse characteristics, including calcium requirement
and subcellular localization, have been identiﬁed. Based on
nucleotide sequences as well as other properties, PLA2s
h a v eb e e nc a t e g o r i z e di n t o1 5g r o u p s( I – X V )[ 11, 12].
Several types of released small PLA2s( ∼14kDa) require
millimolar amounts of calcium for optimal activation. These
enzymes have historically been called the secreted forms
of PLA2 (or sPLA2). The remaining groups are larger
proteins, localized in intracellular compartments, and are
either calcium dependent or independent.
The ﬁrst intracellular PLA2 to be cloned was a protein of
85-kDa, classiﬁed as group IV PLA2 [13, 14]. This enzyme,
now designated as cytosolic PLA2α (cPLA2α), is under the
inﬂuence of extracellular signals likely to induce calcium
mobilization and phosphorylation reactions [13]. Another
group of PLA2 (group VI), which does not require calcium
variations for activity, has been cloned [15–17]. This PLA2
isoform has been designated as calcium-independent PLA2
(iPLA2)( Table 1)[ 14, 18], and according to numerous
lines of biochemical evidence may account for most PLA2
activity under resting conditions. Whereas cPLA2 and sPLA2
are commonly believed to be preferentially involved in AA
release, emerging evidence indicates that iPLA2 activity can
contribute to docosahexaenoic acid (DHA) release from
brain phospholipids. Pharmacologically, iPLA2 activity is
markedly reduced by bromoenol lactone (BEL), a suicide
substrate, which is not an eﬀective inhibitor of sPLA2
or cPLA2 at comparable concentrations [15, 19]. Several
interesting reviews have considered the physiological and
pathological functions of PLA2 enzymes [19–30]. In this
paper, we describe new and unique functional roles of iPLA2
in the regulation of brain glutamate receptor functions,
neuronal plasticity, and neurodegenerative processes.
Among PLA2 enzymes, group IV (cPLA2)a n dg r o u p
VI (iPLA2) families represent intracellular enzymes with a
catalytic serine in their lipase consensus motif. Various stud-
ies, including gene targeting, have indicated that group IVA
cPLA2 (cPLA2α), which is regulated by calcium-dependent
membrane translocation and mitogen-activated protein
kinase-(MAPK-)dependentphosphorylation,isessentialfor
stimulus-dependent eicosanoid biosynthesis [31, 32]. On the
other hand, group VIA iPLA2 (iPLA2β)a n dgr o u pV I B iPLA2
(iPLA2γ) isoforms mainly exhibit phospholipase activity,
whereas the other iPLA2 isoforms δ, ε, ξ,a n dη display
triglyceride lipase and transacylase activities (see Table 1)
[33, 34]. Members of this family share a protein domain
discovered initially in patatin, the most abundant protein
of the potato tuber. Patatin (also called iPLA2α) is a lipid
hydrolase with an unusual folding topology that diﬀers from
classical lipases. The catalytic dyad (Ser-Asp) rather than
the catalytic triad (Ser-His-Asp) is found in classical lipases
and does not contain a lid domain usually required for
interfacial activation [35]. The catalytic dyad is located in a
conserved catalytic domain that shows 40% homology with
patatin/iPLA2α. Adjacent to the catalytic center, there is a
conserved nucleotide binding motif. The iPLA-type enzymes
(i.e., iPLA2β and iPLA2γ) typically possess a long N-
terminal domain, which may be involved in protein-protein
interaction, distinct translation, and membrane spanning.
Like numerous proteins containing the uptake-targeting Ser-
Lys-Leu (SKL) sequence, it has been found that iPLA2g
tightly associated with peroxisomal membranes [36]. The
lipase-type enzymes (i.e., iPLA2 isoforms δ, ε, ξ and η)l a c k
the N-terminal domain and are thought to act primarily
on triglycerides or other neutral lipids in lipid droplets
[37]. Very little is known about the developmental brain
expression of iPLA2 in the brain. In mouse, expression
of iPLA2 enzymes has been reported in sagittal sections
at embryonic day 14.5 [38]. At this stage, the strongest
expression seen in the brain is in the alar plate of the
developing hindbrain with prominent expression also in an
analogous region of the midbrain. IPLA2s also appear to be
expressed in the developing diencephalon and telencephalon
of the forebrain. In situ hybridization studies have revealed
that across several stages of human embryonic and early
fetal development, iPLA2s show a dynamic expression pat-
tern both in terms of the location of expression and the
diﬀerentiation state of expressing cells. In brief, iPLA2sa r e
expressed in forebrain and midbrain before it is detectable
in hindbrain. Throughout the developing brain, iPLA2s
are mainly expressed in proliferative zones, suggesting that
these enzymes are important for early neuronal development
[38]. The precise pattern of expression of both group VIA
iPLA2 (iPLA2β)a n dg r o u pV I B iPLA2 (iPLA2γ) enzymes still
unclear, and one important priority for future studies will be
the precise identiﬁcation of iPLA2 isoforms responsible for
brain development and stabilization.
Group VIA iPLA2β, the most extensively studied iPLA2
isoform, has been implicated in various cellular events,
such as phospholipid remodelling [18, 39], eicosanoid
formation [40], cell growth [41, 42], apoptosis [43], andNeural Plasticity 3
activation of store-operated channels and capacitative cal-
cium inﬂux [44]. Disruption of the iPLA2β gene causes
impaired sperm motility [45], mitigated insulin secretion
[46, 47], and neuronal disorders with iron dyshomeostasis
[48]. Group VIB iPLA2γ is a membrane-bound iPLA2
enzyme with unique features, such as the utilization of
distinct translation initiation sites producing diﬀerent sizes
ofenzymeswithdistinctsubcellularlocalizations[36,49–53]
and phospholipid selectivity in terms of sn-1/sn-2 positional
speciﬁcity, which diﬀers among substrates [54]. iPLA2γ
has a mitochondrial localization signal in the N-terminal
region and a peroxisomal localization signal near the C-
terminus, and the 88-kDa full-length and 63-kDa translation
products of iPLA2γ are preferentially distributed in mito-
chondria and peroxisomes, respectively [49–51]. In brain,
iPLA2 constitutes the predominant phospholipase activity
under resting conditions [55, 56]. Reverse transcription-
polymerase chain reaction experiments have revealed that
rat brain constitutively expresses mRNAs for at least 3
calcium-independent PLA2 isoforms, iPLA2β,i P L A 2γ and
cPLA2γ [16, 57, 58]. These isoforms are characterized by
diﬀerent sensitivity to PLA2 inhibitors, including diﬀerent
enantiomers of an inhibitor; Jenkins et al. [59] established
that the (S)-enantiomer of BEL selectively reduces iPLA2β
activity, while its (R)-enantiomer blocks the iPLA2γ isoform
more eﬃciently.
Although little is known about iPLA2 functions in neu-
rons, a growing body of evidence suggests their involvement
in hippocampal long-term potentiation (LTP) of excitatory
synaptic transmission [55, 60]. Hippocampal LTP, ﬁrst
described by Bliss and Lomo in 1973, is commonly regarded
as a functional model of synaptic adaptation (i.e., plasticity)
thatlikelyparticipates incertainformsoflearningandmem-
ory [61–63]. PLA2 activities are increased in membranes
prepared from the dentate gyrus after LTP induction in
anaesthetized rats [64]; it has been proposed that PLA2 could
be involved in hippocampal LTP expression by elevating the
production of arachidonic acid (AA) that could retrogradely
increase transmitter release at glutamatergic synapses [65,
66]. The hypothesis that facilitation of transmitter release
by PLA2s occurs during LTP is reinforced by the fact that
iPLA2 activity plays an important role in membrane fusion
processes required for exocytosis [21, 67].
The notion that iPLA2 activity may facilitate LTP
expression by increasing glutamate release is contradicted,
however, by a number of reports demonstrating that
synaptic potentiation, at least in area CA1 of hippocam-
pus, is not dependent on changes in transmitter release,
but rather is mediated by upregulation of postsynaptic
responses mediated by alpha-amino-3-hydroxy-5-methyl-4-
isoxazole-propionic acid (AMPA) receptors at glutamatergic
synapses [68, 69]. Several alterations have been reported
at postsynaptic sites during LTP, including faster kinetics
of receptor ion channels [70, 71], redistribution of existing
receptors within the postsynaptic density [72], and insertion
of new receptors at synapses [73, 74]. Consistent with these
observations, we recently demonstrated that pretreatment
of hippocampal slices with the iPLA2 inhibitor BEL com-
pletely abolishes AMPA receptor translocation in synaptic
membranes and expression of CA1 hippocampal LTP [75].
Interestingly, both LTP and AMPA receptor translocation
display enantio-selective impairment by the iPLA2γ blocker
(R)-BEL but not by the iPLA2β inhibitor (S)-BEL, suggesting
that iPLA2γ represents the crucial isoform governing hip-
pocampal synaptic stability. iPLA2γ mRNAs and proteins
are enriched with the endoplasmic reticulum (ER)-Golgi
apparatus in several cell types [57], where they may be
essential for diverse intracellular traﬃcking pathways, such
as retrograde movement from the Golgi complex to the ER,
transport of material from the trans-Golgi network to the
plasma membrane, or recycling of membranes and receptors
through endocytic pathways [21]. In particular, P´ echoux et
al. [76] reported that iPLA2 inhibition slowed down the
transport of caseins from the ER to the Golgi apparatus
and from the trans-Golgi network to the plasma membrane,
indicating that iPLA2 could participate in membrane traf-
ﬁcking events leading to the secretion of milk proteins. Since
AMPA receptors traﬃcking from the ER-Golgi complex to
postsynaptic membranes is critically involved in LTP [77],
the iPLA2γ isoform may be well suited to facilitate AMPA
receptor translocation from intracellular pools to synaptic
membranes during LTP.
Animal experiments have revealed that PLA2 inhibition
resulted in synaptic plasticity impairment and decreased
performance in memory tasks. For instance, intracerebral
injection of wide-spectrum PLA2 inhibitors into chick inter-
mediate medial hyperstriatum ventrale curbs the learning of
a passive avoidance task [78], while intraperitoneal injection
in rats impedes spatial learning in the Morris water maze
[79]. Likewise, intracerebroventricular or intrahippocampal
injection of speciﬁc iPLA2 inhibitors impairs spatial working
memory in rodents [80]. In addition, acquisition of 1-trial
step-down inhibitory avoidance in rats was shown to be
correlated with increased iPLA2 activity in hippocampus,
while bilateral injection of iPLA2 inhibitors in region CA1
of the dorsal hippocampus prior to training hindered both
short-term and long-term memory [81]. In a modiﬁed
protocol developed to test memory retrieval, the same group
recently showed that injection of the dual cPLA2 and iPLA2
inhibitor palmitoyl triﬂuoromethylketone in region CA1
of the rat dorsal hippocampus before performance testing
impaired trained behaviour in the step-down inhibitory
avoidance task [82]. Importantly, memory retrieval was re-
established after recovery of PLA2 activity, indicating that
these PLA2s are indeed necessary for memory stabilization.
Hence, intact iPLA2 activity seems to be critical for proper
memoryacquisitionaswellasretrieval.However,theidentity
of iPLA2 isoforms involved in memory acquisition and
retrieval remains to be determined.
3.iPLA2 andN e ur o nalC ellDeathM ec hanisms
Recently, evidence from studies with nonneuronal cells has
suggestedthatiPLA2 enzymesmayhavediverseeﬀectsoncell
death.First,constitutiveiPLA2 activitymaycontributetocell
death since iPLA2β overexpression ampliﬁes thapsigargin-
induced apoptosis in INS-1 insulinoma cells [83]a n d
accelerates U937 cell death after long-term exposure to4 Neural Plasticity
hydrogen peroxide [84]. iPLA2 has been shown to play a
pivotal role in oxidative damage of astrocytes [85], and its
blockade by BEL dampens oligomeric amyloid-β-( A β1-42-)
inducedmitochondrialmembranepotentiallossandreactive
oxygen species production in these cells [86]. Moreover,
iPLA2 inhibition reduces the size of infarcts produced by
global ischemia [87]. On the other hand, iPLA2 activity has
also been shown to protect against cell death, as inhibition
of iPLA2 accentuates oxidant-induced cell death in renal
proximal tubulecellsand astrocytes[88,89]. Likewise,iPLA2
activity may also have deleterious or beneﬁcial eﬀects on
neurons. For instance, acute inhibition of iPLA2 activity
by racemic BEL has been found to be neuroprotective in
organotypic hippocampal slices exposed to oxygen-glucose
deprivation [90]. In contrast, immature cultures of primary
cortical neurons exposed for several days to BEL showed
decreased cellular viability and neuritic growth [91, 92].
Moreover, iPLA2β knockout mice exhibit abnormal motor
behaviors possibly related to the appearance of vacuoles and
ubiquitin-positive axonal swelling (spheroids) in many brain
regions [93, 94], suggesting that iPLA2β dysfunction leads to
axonal dystrophy.
While the reported impact of iPLA2 on cell viability is
mostly attributable to iPLA2β, involvement of the iPLA2γ
isoform is much less clear. A previous report demonstrated
that iPLA2γ localized in mitochondria catalyzed AA liber-
ation that mediated mitochondrial permeability transition,
a key control point for apoptosis [95]. On the other hand,
iPLA2γ expression may exert cytoprotective eﬀects during
complement-mediated glomerular epithelial cell injury [96].
In addition, recent ﬁndings from our laboratory have
revealed that constitutive iPLA2γ activity might represent
an important neuroprotective system capable of limiting
brain excitotoxic damage. In particular, we showed that
iPLA2γ inhibition by the enantio-speciﬁc inhibitor (R)-
BEL makes cultured hippocampal slices more vulnerable to
AMPA-mediated excitotoxicity [97]. Overactivation of N-
methyl-D-aspartic acid (NMDA) or AMPA receptors results
in a massive entry of calcium into cells, leading to the
activation of a number of enzymes, including ATPases,
lipases, proteases, and endonucleases that, in turn, deplete
energy stores or damage cell membranes, cytoarchitecture
or nuclear components, respectively. Excitotoxicity has been
reported to contribute to a variety of neuropathologi-
cal disorders, including ischemic stroke, epilepsy, amy-
otrophic lateral sclerosis, and Alzheimer’s disease (AD)
[98, 99].
Interestingly, iPLA2γ inhibition-induced enhancement
of AMPA-mediated toxicity is associated with selective
phosphorylation and upregulation of the AMPA receptor
GluR1 but not GluR2 subunits in synaptic membrane
fractions [97, 98, 100]. In hippocampus, AMPA receptors
generally form heterodimers containing 2 copies of each of
the GluR1 and GluR2 subunits. It is now well-recognized
that the presence of GluR2 subunits render AMPA receptors
impermeable to calcium. Consequently, its presence or
absence plays a critical role in cellular calcium homeostasis
andindeterminingsusceptibilitytoexcitotoxicity[101,102].
Hence, iPLA2γ inhibition, by promoting surface expression
o fG l u R 1o v e rG l u R 2s u b u n i t s( w h i c hi sr e ﬂ e c t e db ya
rise in the GluR1/GluR2 ratio in the membrane fraction),
could exacerbate excitotoxic cell death through the increased
formation of GluR2-lacking AMPA receptors that would
allow adverse Ca2+ inﬂux upon prolonged AMPA receptor
activation. Consistent with this possibility, the greater cell
death observed following iPLA2γ inhibition is prevented
by GluR1/3-speciﬁc AMPA receptor antagonists [97]. How
inhibition of iPLA2γ inﬂuences the expression of AMPA
receptor subtypes in synaptic membranes remains an open
question. As mentioned earlier, this may be the result of an
eﬀect of the lipase on protein transport through intracellular
secretory pathways [76]. There are other circumstances in
which GluR1 subunits are selectively upregulated in hip-
pocampal neurons, such as after neuronal activity inhibition
elicited by prolonged blockade of AMPA receptors [103]o r
by tumor necrosis factor-alpha receptor activation [104].
In the latter case, it has been proposed that upregulation
of GluR1 homomeric receptors could be produced by
a reserve pool of non-GluR2-containing AMPA receptors
located near the membrane. Independently of the exact
mechanism, these observations raise the possibility that
constitutive iPLA2γ activity may be a crucial mechanism to
maintain synaptic stability and constitute a molecular device
to prevent neuronal dysfunctions.
4.iPLA2 Dysfunctionand
Neurodegenerative Disorders
As previously described, cPLA2 and sPLA2 are commonly
believed to be preferentially involved in AA release;
emerging evidence indicates that iPLA2 activity can
contribute to docosahexaenoic acid (DHA) release from
brain phospholipids [105]. The ﬁrst suggestion that brain
iPLA2 activity may be crucial for DHA release came from
a study by Strokin et al. [106] who showed that racemic
BEL inhibited DHA release from astrocytes. Later, using
siRNA silencing procedures, the same group demonstrated
that DHA release from astrocytic phospholipids was mainly
dependent on iPLA2γ activity [107]. DHA is one of the
most abundant omega-3 polyunsaturated fatty acids (PUFA)
presentinphospholipidsofmammalianbrain[108],whereit
is recognized to be important for the maintenance of neural
membranes and brain function integrity [109]. Deﬁciency
in dietary intake of DHA has been associated with lower
performance in learning tasks in rodents [110–112]. On
the other hand, DHA dietary supplementation was shown
to decrease the risk of developing AD [113–115]a n dt o
exert neuroprotective actions in a mouse model presenting
numerous aspects of Parkinson’s disease [116], while
high-fat consumption combined with low omega-3 PUFA
intake promoted AD-like neuropathology [117]. Both iPLA2
activity and DHA levels have been reported to be decreased
intheplasmaofADpatients[118,119].LoweriPLA2 activity
has also been reported in AD brains [120, 121]. Whether
or not decreased iPLA2γ activity is a factor contributing
to AD pathology remains to be established. Numerous
neurobiological studies have demonstrated that DHA may
be acting in diﬀerent cellular pathways to counteract severalNeural Plasticity 5
molecular manifestations of AD. There are, for instance,
strong indications that DHA release in the brain may
diminish oxidative stress [122, 123] and glutamate-induced
toxicity [124]. In this line, DHA-induced reduction of
excitotoxic damage in hippocampus might be dependent
on internalization of AMPA receptors [125]. The potential
ability of DHA to reduce caspase activation [114, 115], Aβ
peptide accumulation, and Tau hyperphosphorylation [126,
127] also strongly supports the notion that DHA deﬁciency,
as a result of iPLA2 deﬁciency, could represent a precursor
event that could initiate the cellular manifestations of AD
pathology.
Normally, Tau predominantly localizes to neuronal
axons where it modulates the stability and assembly of
microtubules [128, 129]. In so doing, Tau generates a
partially stable, but still dynamic, state in microtubules
that is important for axonal growth and eﬀective axonal
transport [130]. In addition to binding microtubules, some
but not all studies provide evidence that Tau can interact,
either directly or indirectly, with actin and aﬀect actin
polymerization as well as the interaction of actin ﬁlaments
with microtubules [131, 132]. Furthermore, Tau appears
to interact with the plasma membrane and with several
proteins involved in signal transduction [133–141]. From a
pathologicalperspective,Taudysfunctionresultingfrombio-
chemical defects (i.e., aberrant phosphorylation, truncation,
and glycosylation) has been proposed to be an important
factor contributing to the initiation and development of
several neuropathological conditions such as AD [142–147].
As discussed above, lower iPLA2 activity has been observed
in AD brains and considering our hypothesis that iPLA2γ
is an important factor controlling AMPA-mediated toxicity
in the hippocampus, we anticipated that defect in iPLA2γ
activity can contribute to enhance Tau phosphorylation.
Here, we are presenting the ﬁrst experimental evidence that
Tau become hyperphosphorylated after selective inhibition
of iPLA2γ. We ﬁrst examined Tau phosphorylation levels
at Ser199 residue following treatment of hippocampal slices
with R-BEL and S-BEL, which preferentially block iPLA2γ or
iPLA2β, respectively (see chemical structures; Figure 1(a)).
In initial experiments, we observed that hippocampal tissues
were strongly and consistently stained with an antibody rec-
ognizingthephosphorylatedSer199epitopeofaTauisoform
of 62kDa (Figure 1(b), top panels). As shown in Figure 1,
staining for this hyperphosphorylated Tau isoform increased
followingiPLA2γ inhibitionbyR-BEL.Whentheresultswere
normalized with staining levels of Tau-5 (an antibody that
recognizes Tau independent phosphorylation), it appears
that R-BEL elevated levels of phosphorylated Tau at all
concentrations tested, with a maximal increase of 120±10%
over control values in slices preincubated for 3hr. However,
the same analysis showed that phosphorylation of Tau at
Ser199wasnotalteredbyexposuretotheiPLA2β inhibitorS-
BEL. It is noteworthy that levels of Tau-5 immunoreactivity
in the hippocampal slices were not signiﬁcantly changed by
treatments with either R- or S-BEL, indicating that iPLA2γ
inhibition-induced increases in Ser199 phosphorylation do
not depend on Tau synthesis and/or degradation. De-
Paula and collaborators recently showed that injection of
the dual cPLA2 and iPLA2 inhibitor methyl arachidonyl
ﬂuorophosphonate (MAFP) induced Tau phosphorylation
at Ser214 [148]. In contrast to our results, however, they
reported that Tau hyperphosphorylation was associated with
a reduction in levels of total Tau [149], suggesting that
inhibition of both cPLA2 and iPLA2 might inﬂuence several
biochemical aspects of Tau proteins. Accordingly, recent
experimental results have provided evidence that cPLA2
and iPLA2 activities can play divergent roles during spinal
cord injuries [150]. We recently tested the eﬀect of R-BEL-
mediated iPLA2γ inhibition on Tau subcellular localisation
inCA1pyramidalcells.Usingorganotypichippocampalslice
cultured from transgenic mice expressing human Tau, we
observed that treatment with the speciﬁc iPLA2γ inhibitor
(R)-BEL for up to 12h resulted in increases in Tau phospho-
rylation at the Thr231 site. High-resolution imaging showed
that hyperphosphorylated Tau was primarily localized in the
cell bodies and dendrites of hippocampal pyramidal neurons
(see Figure 2).
One of the central hypotheses for AD pathogenesis
is that the production of cytotoxic Aβ peptides impairs
neuronal activity and leads to a decline in memory and
cognition [151]. Some PLA2 enzymes may exacerbate Aβ
cytotoxicity, as Aβ peptides stimulate cPLA2α activity in
neuronal cultures [86] and primary cortical astrocytes [152];
in addition, Aβ-induced learning and memory deﬁcits in
a transgenic mouse model of AD are prevented by genetic
ablation of cPLA2α activity in brain [152]. On the other
hand, it has been well established that iPLA2 activity is
essential for maintaining membrane phospholipid integrity
by reducing peroxidative damage, especially that originating
in mitochondria. In this regard, iPLA2 expression prevents
thelossofmitochondrialmembranepotentialandattenuates
the release of cytochrome c as well as of other apoptotic
proteins, and ultimately reduces apoptosis in INS-1 cells
exposed to staurosporine [153]. Furthermore, Kinsey et al.
[95, 154] reported that a major component of PLA2 activity
in mitochondria of rabbit renal proximal tubular cells is
provided by iPLA2γ and is of critical importance for the
prevention of basal lipid peroxidation and maintenance of
mitochondrial viability. Based on recent studies, it has been
proposed that Aβ-induced neurotoxicity might derive from
mitochondrial defects. Indeed, in vitro experiments have
shownthatAβpeptidescanbeinternalizedbycells,imported
into mitochondria and ultimately elicit mitochondrial dys-
functions [155]. Given its localization, it is thus tempting
to propose that iPLA2γ might represent an important cel-
lular component that prevents mitochondrial dysfunctions.
Experiments are required to determine whether iPLA2γ
overexpression activity might exert protective eﬀects against
Aβ peptide-induced mitochondrial dysfunctions.
From a pathological perspective, it has been demon-
stratedthatiPLA2 activityisupregulatedinthehippocampus
of patients suﬀering from schizophrenia [156]. The precise
implication of this iPLA2 dysfunction in the development
ofschizophrenia-relatedsymptomsremainsunknown.How-
ever, the results presented above would predict that upreg-
ulation of iPLA2γ activity could eventually lead to reduc-
tion in GluR1-containing receptors. Interestingly, GluR16 Neural Plasticity
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Figure 1: Hippocampal Tau phosphorylation at Ser199 residue is accentuated by R-BEL. Hippocampal slices (350μm) were pre-incubated
at 32◦C for 3h with DMSO alone (control) or with increasing concentrations of the iPLA2γ inhibitor R-BEL or the iPLA2β inhibitor S-BEL
(chemical structures of both compounds are presented in (a)). (b) Phosphorylation and Tau protein levels were determined by Western
blotting of cell extracts (40μg of proteins) obtained from acute hippocampal slices. Phosphorylated Tau levels, expressed relative to total Tau
(i.e., Tau-5; AbCam, Cambridge, MA, USA. Dilution 1:500), were measured using antibodies raised against Tau phosphorylated at Ser199
(AbCam, Cambridge, MA, USA. Dilution 1:1,000). The data were expressed as percentage of control values and are means ± SEM of 3
measurements per cell extract obtained from 7 diﬀerent rats. Statistical analysis was performed by one-way ANOVA followed by Neuman-
Keuls’ post hoc test. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001, drug-treated versus control.
downregulation has been reported to evoke striatal hyper-
dopaminergic activity [157], a well-established biological
defect involved in schizophrenia-related symptoms. The
potential relationship between iPLA2s and the dopaminergic
system is reinforced by the fact that iPLA2 inhibition or
knockdown in rat striatum, motor cortex and thalamus
results in the apparition of Parkinson-related manifestations
[158], which are also known to depend on dopamine
dysfunction. Of course, future experiments will be required
to establish the potential role of iPLA2 enzymes in stabilizing
dopamine-mediated responses.
5. Conclusion
Here, we have summarized growing evidence linking iPLA2γ
activity to the stabilization of synaptic AMPA receptor
properties in hippocampal neurons. First, it appears evident
that without appropriate levels of iPLA2γ activity in area
CA1 of hippocampal slices synaptic stabilization of AMPA
receptors, which is required for the expression of long-term
changes in synaptic strength (i.e., LTP), is compromised.
As mentioned previously, iPLA2γ mRNAs and proteins
are enriched with the endoplasmic reticulum (ER)-Golgi
apparatus in several cell type, where they will be essential for
diverse intracellular traﬃcking pathways, such as retrograde
movement from the Golgi complex to the ER, transport of
material from the trans-Golgi network to the plasma mem-
brane, or recycling of membranes and receptors through
endocytic pathways [21]. Since AMPA receptors traﬃcking
from the ER-Golgi complex to postsynaptic membranes is
critically involved in LTP [77], the iPLA2γ isoform may
be well suited to facilitate AMPA receptor translocation
from intracellular pools to synaptic membranes during
LTP. However, given their biochemical properties andNeural Plasticity 7
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Figure 2: Inhibition of iPLA2γ induces Tau phosphorylation in area CA1 of hippocampus. Cultured hippocampal slices from P301L Tau
transgenic mice were treated with the iPLA2γ inhibitor (R)-BEL. Slices were then processed for confocal immunoﬂuorescence microscopy
with an antibody recognizing Tau phosphorylation at Threonine 231 epitopes (AT231, in green) (AbCam, Cambridge, MA, USA. Dilution
1:750). When compared to controls (upper panel), immunostaining revealed increased phosphorylation in the CA1 region of cultured
hippocampal slices incubated with 3μM (R)-BEL for a period of 12h (lower panel). DAPI (in blue) was included in the mounting medium
to label nuclei. This observation was qualitatively reproduced in hippocampal slices obtained in 3 diﬀerent cultures. Scale bar = 25μm.
GluR1-lacking
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iPLA2
deﬁciency
Hyperphosphorylation
tau proteins
Cdk5 GSK3β
Figure 3: A putative model illustrating the potential implication
of iPLA2γ in Alzheimer’s disease. In this simpliﬁed model, iPLA2
dysfunction leads to excessive delivery of GluR1-containing recep-
tors to neuronal membranes. These receptors are more likely to be
calcium-permeable and therefore to stimulate calcium inﬂux and,
eventually, Tau phosphorylation by calcium-dependent protein
kinases such as Cdk5 and GSK-3β.
localization, future experiments will be required to deter-
mine how the eﬀects of iPLA2γ on LTP might derive from
alterations of other cellular processes controlling synaptic
stability such as regulation of arachidonic acid release,
membrane fusion events, receptor traﬃcking pathways, and
protein kinase activities. Besides, we also documented that
iPLA2γ deﬁciency can destabilize synaptic GluR1 subunits of
AMPA receptors in hippocampl membranes and accentuate
glutamate-induced toxicity. In this line, iPLA2γ-null mice
have been generated [159, 160] and were found to exhibit
phenotypic abnormalities that include altered mitochondrial
morphology, function, and lipid composition associated
with hippocampal degeneration. Interestingly, we provided
here preliminary evidence showing that iPLA2γ activity
appears to be important for stabilizing Tau phosphorylation
in hippocampal pyramidal neurons, suggesting that down-
regulation of iPLA2 activity may contribute to the develop-
ment of tauopathies in AD [161]. A putative biochemical
model that could account for the potential inﬂuence of
iPLA2γ on Tau pathology is presented in Figure 3. Indeed,
considering the growing evidence relating the importance
of iPLA2γ in physiological and pathological conditions,
targeting iPLA2γ activity may represent a potentially new8 Neural Plasticity
therapeutic strategy to address several neurological disorders
characterized with destabilisation of synaptic properties.
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